Boehringer Buys AMAL Therapeutics

18.07.2019 - Germany’s Boehringer Ingelheim has purchased AMAL Therapeutics for an undisclosed sum. AMAL is a private Swiss biotech that is focused on cancer immunotherapy and vaccines derived...